Expert Matthew Lunning, DO, FACP, reviews the case of a 67-year-old man with R/R DLBCL and considers optimal treatment strategies in this setting.
EP. 1: Patient Case: A 67-Year-Old Man With Relapsed/Refractory DLBCL
Expert insights into a 67-year-old man's journey through relapsed/refractory diffuse large B-cell lymphoma, exploring diagnosis, treatment options, and outcomes.
EP. 2: Exploring Treatment Strategies for Lymphoma: CAR T-Cell, Tafasitamab, and Clinical Trials
An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.
EP. 3: DLBCL Clinical Trials: Overview of L-MIND and RE-MIND2
Matthew Lunning, DO, FACP, further explores relapsed/refractory DLBCL treatment strategies and clinical trial findings from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on patient outcomes.
EP. 4: Polatuzumab Vedotin in DLBCL: Trial Data and Treatment Strategies
A deep dive into the use of Polatuzumab Vedotin in DLBCL treatment, including insights from clinical trials and innovative strategies.
EP. 5: CAR T-Cell and Loncastuximab in DLBCL: Clinical Insights and Treatment Considerations
A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.
EP. 6: CD3, CD20 Bispecifics: A New Frontier in DLBCL Treatment
Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
EP. 7: Advancements in Relapsed/Refractory DLBCL: An Evolving Landscape
A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.
2 Clarke Drive Cranbury, NJ 08512